A5035714899- Cancer Genomics and Diagnostics
- Histone Deacetylase Inhibitors Research
- Melanoma and MAPK Pathways
- Genetic factors in colorectal cancer
- Renal cell carcinoma treatment
- Click Chemistry and Applications
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Molecular Biology Techniques and Applications
- Renal and related cancers
- Glioma Diagnosis and Treatment
- Cancer-related molecular mechanisms research
- Genetic Associations and Epidemiology
- Cancer, Lipids, and Metabolism
- Protein Degradation and Inhibitors
- Neuroscience and Neuropharmacology Research
- RNA modifications and cancer
- Synthesis of Tetrazole Derivatives
- Pain Mechanisms and Treatments
- Radiomics and Machine Learning in Medical Imaging
- Single-cell and spatial transcriptomics
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- PI3K/AKT/mTOR signaling in cancer
Genomics (United Kingdom)
2024
University of Cambridge
2016-2023
Cancer Research UK Cambridge Center
2017-2023
Edward Via College of Osteopathic Medicine
2023
Cancer Research UK
2017-2022
Alzheimer’s Research UK
2019-2022
Lumos Pharma (United States)
2021
Vrije Universiteit Amsterdam
2021
Amsterdam University Medical Centers
2021
University of Central Lancashire
2020
Selective sequencing or in silico analysis for differences DNA fragment size can improve the detection of circulating tumor DNA.
Identification of residual disease in patients with localized non-small cell lung cancer (NSCLC) following treatment curative intent holds promise to identify at risk relapse. New methods can detect circulating tumour DNA (ctDNA) plasma fractional concentrations as low a few parts per million, and clinical evidence is required inform their use.
Integration of variant reads across patient-specific mutation loci enables sensitive ctDNA quantification in plasma cell-free DNA sequencing data.
Report6 November 2018Open Access Transparent process Detection of cell-free DNA fragmentation and copy number alterations in cerebrospinal fluid from glioma patients Florent Mouliere Corresponding Author [email protected] orcid.org/0000-0001-7043-0514 Cancer Research UK Cambridge Institute, University Cambridge, Major Centre – Department Pathology, Center Amsterdam, Amsterdam UMC, Vrije Universiteit The NetherlandsSee also: AP Cheng et al (December 2018) Search for more papers by this author...
Abstract Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis. Whilst patients can achieve 6% improvement in overall survival with Neo-Adjuvant Chemotherapy (NAC), many do not respond. Body fluid mutant DNA (mutDNA) may allow non-invasive identification of treatment failure. We collected 248 liquid biopsy samples including plasma, cell pellet (UCP) and supernatant (USN) from spun urine, 17 undergoing NAC. assessed single nucleotide variants copy number alterations mutDNA using...
While elevated blood cholesterol has been associated with an increased risk of colorectal cancer (CRC) in observational studies, causality is uncertain. Here we apply a Mendelian randomisation (MR) analysis to examine the potential causal relationship between lipid traits and CRC risk. We used single nucleotide polymorphisms (SNPs) levels total (TC), triglyceride (TG), low‐density lipoprotein (LDL), high‐density (HDL) as instrumental variables (IV). calculated MR estimates for each factor...
Abstract Background Cell-free tumor-derived DNA (ctDNA) allows non-invasive monitoring of cancers, but its utility in renal cell cancer (RCC) has not been established. Methods Here, a combination untargeted and targeted sequencing methods, applied to two independent cohorts patients ( n = 91) with various tumor subtypes, were used determine ctDNA content plasma urine. Results Our data revealed lower levels RCC relative other cancers similar size stage, detection 27.5% from both cohorts. A...
Current evidence suggests that plasma cell-free DNA (cfDNA) is fragmented around a mode of 166 bp. Data supporting this view has been mainly acquired through the analysis double-stranded cfDNA. The characteristics and diagnostic potential single-stranded damaged cfDNA in healthy individuals cancer patients remain unclear. Here, combination high-affinity magnetic bead-based extraction sequencing library preparation (MB-ssDNA), we report discovery large proportion fragments centered at ∼50 We...
Abstract Background Surgery for renal cell carcinoma (RCC) with venous tumour thrombus (VTT) extension into the vein (RV) and/or inferior vena cava (IVC) has high peri-surgical morbidity/mortality. NAXIVA assessed response of VTT to axitinib, a potent tyrosine kinase inhibitor. Methods was single-arm, multi-centre, Phase 2 study. In total, 20 patients resectable clear RCC and received upto 8 weeks pre-surgical axitinib. The primary endpoint percentage evaluable improvement by Mayo level on...
To study the somatic molecular profile of EGF receptor (EGFR) pathway in advanced colorectal cancer, its relationship to prognosis, site primary and metastases, response cetuximab.
The factors responsible for the low detection rate of cell-free tumor DNA (ctDNA) in plasma patients with glioblastoma (GBM) are currently unknown. In this study, we measured circulating nucleic acids patient-derived orthotopically implanted xenograft (PDOX) models GBM (
Research Article30 May 2018Open Access Transparent process Dynamics of multiple resistance mechanisms in plasma DNA during EGFR-targeted therapies non-small cell lung cancer Dana Wai Yi Tsui orcid.org/0000-0002-0595-6664 Cancer UK Cambridge Institute, Li Ka Shing Centre, University Cambridge, Major Center - Search for more papers by this author Muhammed Murtaza Department Oncology, Alvin Seng Cheong Wong Haematology-Oncology, National Health System, Singapore, Singapore Oscar M Rueda...
Abstract Circulating tumor DNA (ctDNA) in blood plasma is present at very low concentrations compared to cell-free (cfDNA) of non-tumor origin. To enhance ctDNA detection, recent studies have been focused on understanding the non-random fragmentation pattern cfDNA. These investigated fragment sizes, genomic position end points, and motifs. Although these features described shown be aberrant cancer patients, there a lack how individual integrated analysis enrich fraction detection. Using...
Abstract Analysis of circulating tumor DNA (ctDNA) to monitor cancer dynamics and detect minimal residual disease has been an area increasing interest. Multiple methods have proposed but few studies compared the performance different approaches. Here, we compare detection ctDNA in serial plasma samples from patients with breast using tumor‐informed tumor‐naïve assays designed structural variants (SVs), single nucleotide (SNVs), and/or somatic copy‐number aberrations, by multiplex PCR, hybrid...
Overlapping cDNA clones were isolated for human type II procollagen. Nucleotide sequencing of the provided over 2.5 kb new coding sequences pro alpha 1(II) gene and first complete amino acid sequence procollagen from any species. Comparison with published data covering entire lengths I III procollagens made it possible to compare in detail primary structures three most abundant fibrillar collagens. The results indicated that marked preference third base codons glycine, proline alanine...
Abstract Background Recent advances in the study and clinical applications of circulating tumor DNA (ctDNA) are limited by practical considerations sample collection. Whole-genome sequencing (WGS) is increasingly used for analysis ctDNA, identifying copy-number alterations fragmentation patterns. We hypothesized that low-depth/shallow WGS (sWGS) data may be generated from minute amounts cell-free DNA, fragment-size selection remove contaminating genomic small blood volumes. Dried spots have...
Abstract Up to 30% of patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) relapse. Molecular residual disease (MRD) detection using multiple assays after definitive therapy has not been reported. In this study, we included LA-HNSCC (stage III Human Papilloma virus (HPV)-positive, III-IVB HPV-negative) treated curative intent. Plasma was collected pre-treatment, at 4–6 weeks (FU1) 8-12 (FU2) post-treatment. Circulating tumor DNA (ctDNA) analyzed a tumor-informed...